伐昔洛韦治疗早期症状性阿尔茨海默病:VALAD随机临床试验
这项随机临床试验纳入120例早期症状性阿尔茨海默病且HSV血清阳性的成人,比较伐昔洛韦4 g/d与安慰剂。78周时伐昔洛韦组ADAS-Cognitive评分恶化程度大于安慰剂组(组间差异3.93,95%CI 1.03-6.83,P=0.01),作者结论为伐昔洛韦无效,不推荐用于此类人群。
要点
- 78周时伐昔洛韦组ADAS-Cognitive评分变化10.86 vs 安慰剂组6.92,组间差异3.93(95%CI 1.03-6.83,P=0.01)。
- ADCS-ADL评分变化伐昔洛韦组-13.78 vs 安慰剂组-10.16,组间差异-3.62(95%CI -8.16至0.93)。
- 最常见不良事件为血肌酐升高(伐昔洛韦组5例[8.3%] vs 安慰剂组2例[3.3%])。
核心结论
- 伐昔洛韦对主要结局无效且认知恶化,不推荐用于治疗早期症状性阿尔茨海默病且HSV血清阳性的个体。
研究设计与样本
- 随机临床试验,纳入临床诊断为很可能阿尔茨海默病或伴阿尔茨海默病生物标志物阳性的轻度认知障碍成人,HSV-1或HSV-2血清抗体(IgG或IgM)阳性,简易精神状态检查评分18至28。
- 在美国3家记忆障碍专科门诊开展,招募时间2018年1月至2022年5月,末次随访2024年9月。
- 120例参与者随机接受伐昔洛韦4 g/d(n=60)或匹配安慰剂(n=60),平均年龄71.4岁(SD 8.6),55%为女性,93例(77.5%)完成试验。
主要发现
- 78周时11项ADAS-Cognitive子量表评分最小二乘均值变化伐昔洛韦组10.86(95%CI 8.80-12.91) vs 安慰剂组6.92(95%CI 4.88-8.97),组间差异3.93(95%CI 1.03-6.83),P=0.01,伐昔洛韦组认知恶化更重。
- 78周时ADCS-ADL量表评分最小二乘均值变化伐昔洛韦组-13.78(95%CI -17.00至-10.56) vs 安慰剂组-10.16(95%CI -13.37至-6.96),组间差异-3.62(95%CI -8.16至0.93)。
- 78周时18F-florbetapir淀粉样蛋白PET SUVR最小二乘均值变化伐昔洛韦组0.03(95%CI -0.04至0.10) vs 安慰剂组0.01(95%CI -0.06至0.08),组间差异0.02(95%CI -0.08至0.12)。
- 78周时18F-MK-6240 tau PET内侧颞叶SUVR最小二乘均值变化伐昔洛韦组0.07(95%CI -0.06至0.19) vs 安慰剂组-0.04(95%CI -0.15至0.07),组间差异0.11(95%CI -0.06至0.28)。
- 最常见不良事件为血清肌酐升高(伐昔洛韦组5例[8.3%] vs 安慰剂组2例[3.3%])和COVID-19感染(伐昔洛韦组3例[5%] vs 安慰剂组2例[3.3%])。
临床怎么用
- 作者结论为伐昔洛韦无效且不推荐用于治疗早期症状性阿尔茨海默病且HSV血清阳性的个体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neuroscientific, epidemiological, and electronic health record studies implicate herpes simplex virus (HSV) as potentially etiological for Alzheimer disease (AD). OBJECTIVE: To compare the efficacy and adverse effects of valacyclovir vs placebo in participants with early symptomatic AD and HSV seropositivity (HSV-1 or HSV-2). DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial included adults with a clinical diagnosis of probable AD or a clinical diagnosis of mild cognitive impairment with positive biomarkers for AD, a positive serum antibody test (IgG or IgM) for HSV-1 or HSV-2, and a Mini-Mental State Examination score of 18 to 28. The trial was conducted at 3 US outpatient clinics specializing in memory disorders. Recruitment occurred from January 2018 to May 2022; the last follow-up occurred in September 2024. INTERVENTION: Either 4 g/d of valacyclovir (n = 60) or matching placebo (n = 60). MAIN OUTCOMES AND MEASURES: The primary outcome was least-squares mean (LSM) change at 78 weeks in the 11-item Alzheimer's Disease Assessment Scale Cognitive (ADAS-Cognitive) Subscale score (range, 0-70; higher scores indicate greater impairment). The secondary outcomes were LSM change in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Scale score; LSM change in the 18F-florbetapir amyloid positron emission tomography (PET) standardized uptake value ratio (SUVR; higher scores indicate higher amyloid levels) for 6 brain regions (medial orbitofrontal, anterior cingulate, parietal lobe, posterior cingulate, temporal lobe, and precuneus); and LSM change in 18F-MK-6240 tau PET medial temporal SUVR (higher scores indicate higher tau levels) for 4 brain regions (amygdala, hippocampus, entorhinal, and parahippocampus). The frequency of adverse events was the safety outcome. RESULTS: Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial. At 78 weeks, the LSM change in the 11-item ADAS-Cognitive Subscale score was 10.86 (95% CI, 8.80 to 12.91) in the valacyclovir group vs 6.92 (95% CI, 4.88 to 8.97) in the placebo group, indicating greater cognitive worsening with valacyclovir than placebo (between-group difference, 3.93 [95% CI, 1.03 to 6.83]; P = .01). The LSM change in the ADCS-ADL Scale score at 78 weeks was -13.78 (95% CI, -17.00 to -10.56) in the valacyclovir group vs -10.16 (95% CI, -13.37 to -6.96) in the placebo group (between-group difference, -3.62 [95% CI, -8.16 to 0.93]). At 78 weeks, the LSM change in the 18F-florbetapir amyloid PET SUVR was 0.03 (95% CI, -0.04 to 0.10) in the valacyclovir group vs 0.01 (95% CI, -0.06 to 0.08) in the placebo group (between-group difference, 0.02 [95% CI, -0.08 to 0.12]). The LSM change in the 18F-MK-6240 tau PET medial temporal SUVR at 78 weeks was 0.07 (95% CI, -0.06 to 0.19) in the valacyclovir group vs -0.04 (95% CI, -0.15 to 0.07) in the placebo group (between-group difference, 0.11 [95% CI, -0.06 to 0.28]). The most common adverse events were elevated serum creatinine level (5 participants [8.3%] in the valacyclovir group vs 2 participants [3.3%] in the placebo group) and COVID-19 infection (3 [5%] vs 2 [3.3%], respectively). CONCLUSIONS AND RELEVANCE: Valacyclovir was not efficacious with cognitive worsening for the primary outcome and it is not recommended to treat individuals with early symptomatic AD and HSV seropositivity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03282916.
引用
- Devanand DP, Wisniewski T, Razlighi Q, et al. Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial. JAMA. 2026. PMID: 41405855. doi:10.1001/jama.2025.21738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。